- Trials with a EudraCT protocol (978)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
978 result(s) found for: Colorectal.
Displaying page 15 of 49.
| EudraCT Number: 2009-013279-23 | Sponsor Protocol Number: NCT-2008-11-02-1020 | Start Date*: 2010-03-04 | |||||||||||
| Sponsor Name:University Hospital of Heidelberg | |||||||||||||
| Full Title: In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study | |||||||||||||
| Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003838-24 | Sponsor Protocol Number: GEMCAD-1602 | Start Date*: 2018-03-12 | |||||||||||
| Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) | |||||||||||||
| Full Title: A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. | |||||||||||||
| Medical condition: MSS colorectal adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003049-17 | Sponsor Protocol Number: CR11 | Start Date*: 2007-01-08 | |||||||||||
| Sponsor Name:Medical Research Council | |||||||||||||
| Full Title: A two-arm randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of metastatic colorectal cancer | |||||||||||||
| Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001639-38 | Sponsor Protocol Number: GEMCAD-16-03 | Start Date*: 2017-07-19 | |||||||||||
| Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) | |||||||||||||
| Full Title: A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good ... | |||||||||||||
| Medical condition: First-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002023-41 | Sponsor Protocol Number: CRC1 | Start Date*: 2013-10-28 | |||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||
| Full Title: Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRC | |||||||||||||
| Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004944-27 | Sponsor Protocol Number: NIPEC-OXA | Start Date*: 2021-03-09 | |||||||||||
| Sponsor Name:Oslo Universtity Hospital | |||||||||||||
| Full Title: NORMOTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN PERITONEAL METASTASES FROM COLORECTAL CANCER – FEASIBILITY STUDY (NIPEC-OXA) | |||||||||||||
| Medical condition: Metastases from Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000451-12 | Sponsor Protocol Number: BNT122-01 | Start Date*: 2021-03-19 | |||||||||||||||||||||
| Sponsor Name:BioNTech SE | |||||||||||||||||||||||
| Full Title: A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patie... | |||||||||||||||||||||||
| Medical condition: Colorectal cancer (Stage II [high risk] and Stage III) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date*: 2023-04-24 | ||||||||||||||||
| Sponsor Name:Amsterdam University Medical Centers | ||||||||||||||||||
| Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
| Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004162-99 | Sponsor Protocol Number: RAMTAS | Start Date*: 2018-08-09 | |||||||||||
| Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
| Full Title: RAMTAS A Phase III study of RAMucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients | |||||||||||||
| Medical condition: Advanced metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000820-42 | Sponsor Protocol Number: EFC10262 | Start Date*: 2008-06-24 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan... | |||||||||||||
| Medical condition: Patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) GR (Completed) NL (Completed) CZ (Completed) EE (Completed) ES (Completed) DK (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000158-88 | Sponsor Protocol Number: 2019-013-GLOB1 | Start Date*: 2020-07-27 | ||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | ||||||||||||||||||
| Full Title: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients wit... | ||||||||||||||||||
| Medical condition: Refractory metastatic colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Prematurely Ended) FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) CZ (Completed) PL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-003767-10 | Sponsor Protocol Number: GEMCAD-2102 | Start Date*: 2022-03-31 | |||||||||||
| Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) | |||||||||||||
| Full Title: Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). | |||||||||||||
| Medical condition: Homologous-recombination repair deficient (HRD) advanced colorectal cancer (CRC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004782-39 | Sponsor Protocol Number: DS8201-A-U207 | Start Date*: 2021-05-21 | |||||||||||
| Sponsor Name:Daiichi Sankyo Inc. | |||||||||||||
| Full Title: A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02) | |||||||||||||
| Medical condition: HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001855-22 | Sponsor Protocol Number: M14AFS | Start Date*: 2015-01-14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-004392-32 | Sponsor Protocol Number: MS100070-0028 | Start Date*: 2018-05-25 | ||||||||||||||||
| Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | ||||||||||||||||||
| Full Title: CAVE (Cetuximab-AVElumab) mCRC: A single arm phase IIclinical study of the combination of avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients. | ||||||||||||||||||
| Medical condition: Metastatic colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-005287-10 | Sponsor Protocol Number: 2012-PT023 | Start Date*: 2015-08-03 | |||||||||||
| Sponsor Name:XBiotech Germany GmbH | |||||||||||||
| Full Title: A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) PL (Completed) BE (Completed) CZ (Completed) ES (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004752-77 | Sponsor Protocol Number: 20070820 | Start Date*: 2009-03-18 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irin... | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) ES (Completed) IT (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005547-27 | Sponsor Protocol Number: GO28074 | Start Date*: 2012-10-24 | |||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | |||||||||||||||||||||||
| Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ... | |||||||||||||||||||||||
| Medical condition: Colorectal cancer that does not carry mutation in the KRAS gene | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-003151-41 | Sponsor Protocol Number: CL3-95026-001 | Start Date*: 2022-01-25 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to trifluridine/tipiracil single agent with a Safety Lead-In... | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) BE (Completed) FI (Completed) HU (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004030-32 | Sponsor Protocol Number: AIOKRK0306 | Start Date*: 2007-01-04 | |||||||||||
| Sponsor Name:Klinikum der Ludwig-Maximilians Universität München, Klinikum Großhadern | |||||||||||||
| Full Title: Randomisierte Studie zur Wirksamkeit von FOLFIRI in Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen Karzinoms English translation: Ra... | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.